Fortress Biotech, Inc. (NASDAQ:FBIO) is expected to post earnings of -$0.21 per share

Analysts expect Fortress Biotech, Inc. (NASDAQ:FBIO – Get Rating) to report earnings per share (EPS) of ($0.21) for the current fiscal quarter, according to Zacks. Five analysts provided earnings estimates for Fortress Biotech. The lowest EPS estimate is ($0.37) and the highest is ($0.06). Fortress Biotech reported earnings of ($0.11) per share in the same quarter last year, suggesting a negative year-over-year growth rate of 90.9%. The company is expected to release its next quarterly results on Monday, January 1.

According to Zacks, analysts expect Fortress Biotech to report annual earnings of ($0.75) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to ($0. $30). For the next fiscal year, analysts expect the company to post earnings of $0.10 per share, with EPS estimates ranging from ($1.45) to $2.19. Zacks Investment Research EPS averages are an average average based on a survey of sell-side research companies that track Fortress Biotech.

Fortress Biotech Inc (NASDAQ:FBIO – Get Rating) last released its quarterly earnings data on Monday, March 28. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.08 per ($0.46). Fortress Biotech had a negative return on equity of 27.80% and a negative net margin of 94.06%.

FBIO has been the subject of several recent research reports. StockNews.com downgraded shares of Fortress Biotech from a “hold” rating to a “sell” rating in a Tuesday, March 29 research note. Roth Capital reaffirmed a “buy” rating on Fortress Biotech shares in a Tuesday, March 29 research note. Zacks Investment Research downgraded shares of Fortress Biotech from a “held” rating to a “strong sell” rating in a Thursday, March 31 research note. Finally, TheStreet downgraded shares of Fortress Biotech from a “c-” rating to a “d+” rating in a Monday, February 14 research note. Two equity research analysts rated the stock with a sell rating and four gave the company a buy rating. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $9.30.

FBIO traded $0.05 on Tuesday during trading hours, hitting $1.15. 823,173 shares of the company were traded, against an average volume of 501,767. Fortress Biotech has a 12-month low of $1.09 and a 12-month high of $5.05. The company has a 50-day moving average of $1.55 and a 200-day moving average of $2.37. The company has a market capitalization of $120.17 million, a P/E ratio of -1.46 and a beta of 2.29. The company has a current ratio of 3.43, a quick ratio of 3.33 and a debt ratio of 0.21.

Major investors have recently changed their positions in the company. Citigroup Inc. increased its position in Fortress Biotech shares by 160.5% in the third quarter. Citigroup Inc. now owns 8,879 shares of the biopharmaceutical company valued at $29,000 after buying an additional 5,470 shares in the last quarter. Marshall Wace LLP bought a new stock position in Fortress Biotech in Q4 worth $30,000. Two Sigma Securities LLC bought a new stock position in Fortress Biotech in Q3 worth $33,000. BNP Paribas Arbitrage SA increased its position in Fortress Biotech shares by 319.9% ​​in the third quarter. BNP Paribas Arbitrage SA now owns 12,459 shares of the biopharmaceutical company valued at $40,000 after buying an additional 9,492 shares in the last quarter. Finally, ProShare Advisors LLC bought a new position in Fortress Biotech stock in Q4 worth $41,000. 30.77% of the shares are currently held by institutional investors.

Fortress Biotech Company Profile (Get a rating)

Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of moderate to severe non-nodular acne vulgaris; Targadox for severe acne; Exelderm cream for symptoms of ringworm and jock itch; Ceracade for dry skin; Luxamend for dressing and treating wounds; and Accutane capsules for severe recalcitrant nodular acne.

Featured articles

Get a Free Copy of Zacks’ Research Report on Fortress Biotech (FBIO)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Get news and reviews for Fortress Biotech Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fortress Biotech and related companies with MarketBeat.com’s free daily email newsletter.